KRAS and colorectal carcinoma: Notably, they discovered that PI3K/AKT, MEK, and FGFR inhibitors were particularly effective for the KM2 subtype, while fluorouracil and CDK inhibitors showed higher efficacy in treating the KM1 subtype.418 This sophisticated molecular stratification provides crucial insights for crafting targeted and potent therapeutic strategies for KRAS-mutant CRC.